Slow‐release vaginal insert of misoprostol versus orally administrated solution of misoprostol for the induction of labour in primiparous term pregnant women: a randomised controlled trial
Authors:
- 16 April 2019
- journal article
- research article
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 126 (9) , 1148-1155
Abstract
Objective: To compare the World Health Organization (WHO) recommended orally administrated dosage of misoprostol (25 μg) with a vaginal slow‐release (7 μg/hour) insert of misoprostol regarding time from induction to delivery and safety of the method.Design: Open label, Randomised controlled trial (RCT).Setting: Delivery ward at a secondary referral hospital in Stockholm, Sweden, from 1 October 2016 to 21 February 2018.Population: One hundred and ninety‐six primiparous women with singletons in cephalic presentation at ≥37 weeks of gestation and with a Bishop score of ≤4.Methods: Women were randomised to an oral solution of misoprostol (Cytotec® n = 99) or vaginal slow‐release misoprostol (Misodel® [MVI] n = 97).Main outcome measures: Primary outcome: time from induction to vaginal delivery. Secondary outcomes: mode of delivery; proportion of vaginal deliveries within 24 hours (VD24); neonates with an Apgar score of 1000 ml; hyperstimulation; and women's delivery experience (VAS).Results: There was no difference in the time to vaginal delivery (median 21.1 hours in the MVI group and 23.2 hours in the oral group; Kaplan–Mayer log rank P = 0.31). There was no difference regarding the proportion of VD24 (50.5 versus 55.7%, P = 0.16). Hyperstimulation with non‐reassuring cardiotocography (CTG) was more common in the MVI group (14.4 versus 3.0%, P < 0.01). Terbutaline (Bricanyl®) was used more often for hyperstimulation in the MVI group (22.7 versus 4.0%, P < 0.01). There was no difference in the numbers of children admitted to the neonatal intensive care unit (NICU).Conclusions: Vaginal delivery after induction of labour (IOL) with slow‐release misoprostol did not result in a shorter time from induction to vaginal delivery, compared with oral misoprostol solution, but was associated with a higher risk for hyperstimulation and fetal distress. There were no differences in mode of delivery or neonatal outcome.Tweetable IOL with MVI was similar to oral solution of misoprostol but hyperstimulation and fetal distress were more common.Keywords
This publication has 16 references indexed in Scilit:
- Oral misoprostol is as safe as Foley catheter for labour induction…or is it?The Lancet, 2016
- Induction of labour at term with oral misoprostol versus a Foley catheter (PROBAAT-II): a multicentre randomised controlled non-inferiority trialThe Lancet, 2016
- Misoprostol for induction of laborSeminars in Perinatology, 2015
- Overview of the mechanisms of induction of laborSeminars in Perinatology, 2015
- Misoprostol Vaginal Insert and Time to Vaginal DeliveryObstetrics & Gynecology, 2013
- WHO recommendations for misoprostol use for obstetric and gynecologic indicationsInternational Journal of Gynecology & Obstetrics, 2013
- Methods of induction of labour: a systematic reviewBMC Pregnancy and Childbirth, 2011
- Induction of labor and the risk for emergency cesarean section in nulliparous and multiparous womenActa Obstetricia et Gynecologica Scandinavica, 2011
- Misoprostol Vaginal Insert for Successful Labor InductionObstetrics & Gynecology, 2011
- Systematic review: Misoprostol compared with prostaglandin E2 for labour induction in women at term with intact membranes and unfavourable cervix: a systematic review*BJOG: An International Journal of Obstetrics & Gynaecology, 2006